• Home
  • News
  • Market Data
  • Participants
  • Issuers
  • Investors
  • Education
  • Profile

Cookie notification

Our website uses cookies. This enables us to optimize your user experience. By continuing to use our website, you agree to this. To find out more, please see our Privacy Policy.


News - Third listing on SIX Swiss Exchange in a week



23.03.2018 Issuers

Third listing on SIX Swiss Exchange in a week

Medartis joins the attractive life sciences universe on the Swiss stock exchange.

With an opening price of CHF 54.00 Medartis (MED) has successfully listed its shares on SIX Swiss Exchange (IPO video). This corresponds to a market capitalization of CHF 633 Mio. The issued share capital of Medartis comprises 11'730'353 registered shares with a nominal value of CHF 0.20 per share. The company has offered 2'994'791 newly registered shares and thereby raising around CHF 142.6 Mio. in gross proceeds including all the over-allotment shares. At the opening price of CHF 54.00 per share, the placement volume corresponds (including all the over-allotment shares) to an amount of around CHF 161.7 Mio. The company has granted the Joint Global Coordinators of the offering an over-allotment option of 390'625 newly registered shares. Medartis shares will be listed in the "International Reporting Standard" and included in the SPI® as well as in the SXI Life Sciences® and SXI Bio+Medtech® indices.

Basel-based Medartis specializes in high-precision implants for surgical treatment of bone fractures and osteotomies. Thomas Straumann, founder and Chairman of Medartis: "The IPO marks an important milestone in the development of Medartis and will allow us to take the company to the next level. There are numerous opportunities for us to grow, and the timing is right for us to offer shares and seek a listing, in order to be in a strong position to capture these favorable prospects."

Thomas Straumann, Chairman of the Board of Medartis and Willi Miesch, CEO Medartis

Leading European stock exchange in the life sciences sector

The IPO of another company in the life sciences sector underlines the leadership of the Swiss stock exchange in this industry. With around 40% of life sciences free float market capitalization, SIX Swiss Exchange is the leading stock exchange in this sector in Europe.

"Both Switzerland as a financial center and SIX Swiss Exchange offer life sciences companies an ideal growth environment, with efficient access to the capital of a specialized and experienced group of investors," comments Werner Bürki, Deputy CEO Swiss Exchange. "Companies also benefit from a peer universe with sector champions such as Novartis, Roche and Lonza."

Numerous benefits for equity issuers

A listing on SIX Swiss Exchange provides companies with access to strongly capitalized Swiss and international investors. In addition, we make things as simple as possible for them with first-class, needs-oriented services, allowing issuers to efficiently raise capital and achieve sustainable growth. Our appeal extends far beyond the borders of Switzerland.

An overview and helpful information on all topics relevant to going public on SIX Swiss Exchange can be found in the comprehensive Going Public Guide or in the compact "IPO Guide Schweiz" (available only in German). Further information on our range of services for issuers can be found on our website.


Show all news